Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV-1, Drug Therapy, Combination, HIV Protease Inhibitors, Ritonavir, RNA, Viral, Reverse Transcriptase Inhibitors, Viral Load, ABT 378, tenofovir disoproxil, VX-175, Treatment Experienced
Eligibility Criteria
Note: Accrual into A5143 and A5147S has been discontinued. The study originally planned to enroll 216 participants, but only 56 participants were enrolled at the time of early termination of enrollment because of interim review results. Inclusion Criteria for Step 1 HIV infected Past anti-HIV therapy consisting of at least 1 PI-containing regimen or detectable viral load, and at least 1 year total anti-HIV therapy experience Viral load of more than 5000 copies/ml within 60 days prior to screening while on a stable anti-HIV therapy for at least 12 weeks Agree to use acceptable forms of contraception Exclusion Criteria More than 7 days of treatment with LPV and/or more than 7 days of treatment with APV or fosamprenavir HIV vaccine within 90 days of study entry Experimental drugs within 30 days of study entry Cancer chemotherapy within 30 days of study entry Drugs that affect the immune system within 30 days of study entry Certain drugs within 14 days of study entry. Patients who have used drugs that might damage the kidneys within 7 days of study entry are allowed. Midazolam within 7 days of study entry Allergic or sensitive to study drugs Excessive drug or alcohol use Serious illness requiring treatment and/or hospitalization and have not completed therapy, or are not stable on therapy for at least 14 days prior to study entry Pregnant or breastfeeding
Sites / Locations
- USC CRS
- Ucsf Aids Crs
- The Ponce de Leon Ctr. CRS
- Indiana Univ. School of Medicine, Infectious Disease Research Clinic
- Indiana Univ. School of Medicine, Wishard Memorial
- Methodist Hosp. of Indiana
- HIV Prevention & Treatment CRS
- Univ. of Cincinnati CRS
- Case CRS
- MetroHealth CRS
- The Ohio State Univ. AIDS CRS
- Vanderbilt Therapeutics CRS
- University of Washington AIDS CRS